Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

Medical Science Monitor

Volumn 23, Issue , 2017, Pages 315-324

  Shen, Jinwen ^a,b   Zhu, Yuan ^a,b   Wu, Wei ^a   Zhang, Lingnan ^a   Ju, Haixing ^a   Fan, Yongtian ^a   Zhu, Yuping ^a   Luo, Jialin ^a,b   Liu, Peng ^a,b   Zhou, Ning ^a,b   Lu, Ke ^a,b   Zhang, Na ^a,b   Li, Dechuan ^a   Liu, Luying ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Zhejiang Key Laboratory of Pharmaceutical Technology   (China)

Author keywords

Chemoradiotherapy; Neutrophils; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PERINEURAL INVASION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RECTUM BIOPSY; RECTUM CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; BLOOD; CHEMORADIOTHERAPY; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTOR;

AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 85010411128     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.902752     Document Type: Article

References (32)

1. Siegel R, Ma J, Zou Z et al: Cancer statistics, 2014. Cancer J Clin, 2014; 64(1): 9-29
2. Glynne-Jones R, Kronfli M: Locally advanced rectal cancer: A comparison of management strategies. Drugs, 2011; 71(9): 1153-77
3. Howlader N, Noone AM, Krapcho M et al. (eds.): SEER Cancer Statistics Review, 1975-2011, National Cancer Institute
4. Sauer R, Becker H, Hohenberger W et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004; 351(17): 1731-40
5. Zorcolo L, Rosman A S, Restivo A et al: Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: A meta-analysis. Ann Surg Oncol, 2012; 19(9): 2822-32
6. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al: Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol, 2011; 18(6): 1590-98
7. Maas M, Nelemans PJ, Valentini V et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol, 2010; 11(9): 835-44
8. Mohiuddin M, Hayne M, Regine WF et al: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys, 2000; 48(4): 1075-80
9. Theodoropoulos G, Wise WE, Padmanabhan A et al: T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum, 2002; 45(7): 895-903
10. Roxburgh CS, Salmond JM, Horgan PG et al: The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg, 2009; 13(11): 2011-19
11. Galon J, Fridman WH, Pagès F: The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res, 2007; 67(5): 1883-86
12. Satomi A, Murakami S, Ishida K et al: Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol, 1995; 34(1): 69-73
13. Yang X, Huang Y, Feng JF et al: Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: A meta-analysis. Onco Targets Ther, 2015; 8: 789-94
14. Chen J, Hong D, Zhai Y et al: Meta-analysis of associations between neutrophil-to-lymphocyte ratio and prognosis of gastric cancer. World J Surg Oncol, 2015; 13(1): 1-9
15. Xiao W K, Chen D, Li S Q et al: Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. BMC Cancer, 2014; 14(1): 1-10
16. Huang C, Yue J, Li Z et al: Usefulness of the neutrophil-to-lymphocyte ratio in predicting lymph node metastasis in patients with non-small cell lung cancer. Tumour Biol, 2015; 36(10): 1-9
17. Hung HY, Chen JS, Yeh CY et al: Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 2011; 26(8): 1059-65
18. Carruthers R, Tho LM, Brown J et al: Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis, 2012; 14(10): e701-7
19. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1997; 12(1): 19-23
20. Kim IY, You SH, Kim YW: Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg, 2014; 14(1): 1-7
21. Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB et al: Pre-operative neutrophils/lymphocyte ratio in rectal cancer patients with preoperative chemoradiotherapy. Med Arch, 2016; 70(4): 256-60
22. Walsh SR, Cook EJ, Goulder F et al: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 2005; 91(3): 181-84
23. Benson AB, Schrag D, Somerfield MR et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 2004; 22(16): 3408-19
24. Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol, 2012; 10(6): 639-45
25. Burn J, Gerdes AM, Macrae F et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. J Dig Oncol, 2011; 378(378): 2081-87
26. Guthrie GJ, Roxburgh CS, Farhanalanie OM et al: Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer, 2013; 109(1): 24-48
27. Dong YW, Shi YQ, He LW et al: Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: A meta-analysis. Onco Targets Ther, 2016; 9: 3127-34
28. Zhu J, Liu F, Gu W et al: Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: Results of a phase II study. Radiat Oncol, 2014; 9(1): 217-25
29. Huh J W, Kim HR, Kim YJ: Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum, 2013; 56(6): 698-703
30. Shen JW, Liu LY, Li DC et al: [Relationships between preoperative systemic inflammatory response and clinicopathological characteristics in patients with resectable colorectal cancer.] China Journal of Modern Medicine, 2016; 26(21): 87-93 [in Chinese]
31. Shen L, Zhang H, Liang L et al: Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol, 2014; 9(1): 295
32. Nagasaki T, Akiyoshi T, Fujimoto Y et al: Prognostic impact of neutrophilto-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy. Dig Surg, 2015; 32(6): 496-503